AHPA
Omniab, Inc.
A "blank check" company, or special purpose acquisition company (SPAC), formed by the private equity firm Avista Healthcare Partners in 2021 to find a healthcare business to take public. It served its purpose in late 2022 when it merged with OmniAb, an antibody discovery company spun off from Ligand Pharmaceuticals, and the combined company began trading under the new name OmniAb. The deal followed the path of its sibling SPAC, which had earlier merged with wound-care maker Organogenesis.
SPACUnderlying: AHPACUSIP: G07247102HealthcareUS
Common Stock — Merged with OmniAb; became OABI Nov 1, 2022
No tracked superinvestors held this security in this period.